Q2 EPS Estimates for AnaptysBio Increased by Leerink Partnrs

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of AnaptysBio in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will earn ($0.89) per share for the quarter, up from their prior estimate of ($1.07). The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($4.11) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($2.88) EPS, FY2028 earnings at ($2.86) EPS and FY2029 earnings at ($2.63) EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million.

ANAB has been the subject of several other research reports. JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 1st. HC Wainwright restated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th. Wells Fargo & Company increased their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Finally, Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.88.

AnaptysBio Stock Up 0.1 %

ANAB traded up $0.01 during trading on Thursday, hitting $19.59. 421,018 shares of the company traded hands, compared to its average volume of 597,975. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The stock's fifty day moving average is $18.63 and its 200 day moving average is $18.59. The firm has a market cap of $579.35 million, a P/E ratio of -3.22 and a beta of -0.20.

AnaptysBio announced that its Board of Directors has initiated a stock buyback program on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE raised its stake in AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 979 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 1,858 shares during the last quarter. Tower Research Capital LLC TRC grew its position in AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in AnaptysBio in the fourth quarter valued at $40,000. Finally, AlphaQuest LLC raised its position in AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.